
10

15



- Use of at least two compounds chosen from components having an a) anti-radical, b) anti-inflammatory and c) anti-allergic /activity for the preparation of a composition exhibiting at least two of the a), b) and c) activities intended for the treatment of sensitive and/or allergic skin.
- Use according to qlaim 1, characterized in that the a), b) and c) activities are exerted in the composition. -
- Use according to either of Claims 1 and 2, characterized in that the component or components exhibiting an anti-radical activity are chosen from freeradical scavengers, ant f-lipoperoxidants and stimulants of the endogenous production of the enzymes which degrade free radicals.
- Use according to one of Claims 1 to 3, characterized in that the / components exhibiting an antiinflammatory activity are chosen from prostaglandin inhibitors of cytokine production and
- 20 inhibitors, inhibitors of leukotr/iene production.
  - Use according to one of Claims 1 to 4, characterized in that the anti-allergic components are chosen from inhibitors of typhocyte proliferation, inhibitors
- of the internalization of HLA receptors and inhibitors of 25 cytokine production
  - Use according to/one of Claims 1 to 5, characterized in that the composition inhibits the synthesis or the expression of heuromediators by cutaneous cells.
- 30 Use according to one of Claims 1 to 6, characterized in that at least one component is chosen from the following group: dinkgo biloba and its extracts, iramine, D-panthenol,  $\beta$ -sitosterol, modulene,  $\alpha$ -tocopherol and its derivatives,  $\alpha$ -t $\beta$ copherol phosphate,  $\beta$ -glucan and its derivatives, ei¢osapentanoic acid, 18\$-glycyrrhetinic 35
  - glycyrrhetinic acid monoglucuronide, glycyrrhetinate, Scutellaria extract, lactoferrin, green tea extract, vitamin C, glutathione, epidermal thymus

factor, imidazole derivatives, triazole derivatives and lipacid,

and with the condition that the combination vitamin E and Scutellaria extract is excluded.

- 5 8. Use according to Claim 7, characterized in that at least two components are chosen from the following group: Ginkgo biloba and its extracts, iramine, D-panthenol, β-sitosterol modulene, α-tocopherol and its derivatives, α-tocopherol phosphate, β-glucan and its
- derivatives, eicosapentanoic acid, 18\$\beta\$-glycyrrhetinic acid, glycyrrhetinic acid monoglucuronide, stearyl glycyrrhetinate, scutellaria extract, lactoferrin, green tea extract, vitamin C, glutathione, epidermal thymus factor, imidazele derivatives, triazole derivatives and lipacid,
- and with the condition that the combination vitamin E and Scutellaria extract is excluded.
- 9. Use of at least two compounds according to one of Claims 1 to 8 for the preparation of a medicament intended for the preatment of a complaint chosen from atopy, psoriasis, erythema multiforme, xerodermatitides, systemic lupus erythematosus, pemphigus, dermatitides, rosacea, neurodermatitides and alopecia.
- 10. Use according to one of Claims 1 to 9, characterized in that the composition contains at least one of the following combinations: α-tocopherol/Ginkgo biloba extract, carboxymethyl-β-glucan/Ginkgo biloba extract, β-sitosterol/D-panthenol, drieline/lactoferrin and panthenol/green tea extract.
- 30 11. Method for the cosmetic treatment of sensitive skin, characterized in that a dermocosmetic composition which contains a synergic combination of at least two components chosen from
  - a) anti-radicals,
- 35 b) anti-inflammatories,
  - c) anti-allergids is applied on the region concerned, the said components being chosen so that the final composition exhibits at least two of the a), b) and/or c) activities.

15

- 12. Process for the preparation of a composition with hypoallergenic or immunomodulatory activity and/or which is intended for the treatment of sensitive skin, characterized in that it comprises the stages during which
- 5 a) components are selected which exhibit at least one anti-inflammatory, anti-radical and/or anti-allergic activity, at least two components exhibiting at least two different activities are then combined and it is determined if at least one of the activities is potentiated by the combination of these two components,
  - b) the combinations exhibiting at least two of the activities chosen from the anti-inflammatory, anti-radical and anti-allergic activities, and in which at least one of the activities is potentiated, are selected,
  - c) at least one of the selected combinations is mixed with dermatologically or cosmetologically acceptable excipients, in order to obtain the composition.
- 20 13. Composition capable of being obtained by the process according to Claim 12, characterized in that it contains at least one, preferably at least two, components chosen from the group consisting of Ginkgo biloba and its extracts, iramine, D-panthenol, modulene,
- 25 α-tocopherol and its derivatives, β-glucan and its derivatives, eigosapentanoic acid, 18β-glycyrrhetinic acid, glycyrrhetinic acid monoglucuronide, stearyl glycyrrhetinate, Scutellaria extract, lactoferrin, green tea extract, vitamin C, glutathione, epidermal thymus
- factor, azole derivatives and lipacid, and with the condition that the combination vitamin E and Scutellaria extract is /excluded.
  - 14. Composition according to Claim 13, characterized in that it contains a synergic combination of a Ginkgo biloba extract and of  $\beta$ -glucan or of one of its derivatives.
  - 15. Composition according to either of Claims 13 and 14, characterized in that the  $\beta$ -glucan is substituted by carboxymethyl groups.

- Composition/according to one of Claims 13 to 15, characterized in that the terpene concentration in the Ginkgo biloba extract is less than 1% w/w of dry matter.
- Composition according to one of Claims 13 to 16, characterized in that the concentration of Ginkgo biloba extract is between 0.001% and 10% w/w.
  - Composition according to one of Claims 13 to 17, characterized in / that the eta-glucan concentration is between 0.001% and 10% w/w.
- Composition according to Claim 13, characterized 10 in that it contains a combination chosen from drieline + lactoferrin, panthenol + green tea extract or D-panthenol +  $\beta$ -sitostero1.
  - 20. Composition according to one of Claims 13 to 19. characterized in that it additionally contains at least one other active principle which is active by the cutaneous tpical route.
  - Composition according to Claim 20, characterized in that it/contains at least one active principle chosen from the  $\phi$ roup of retinoids and depigmenting agents.

20

, M